Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.
about
Diagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvementMechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone RemodelingComputational modeling of interactions between multiple myeloma and the bone microenvironmentMulti-Scale Agent-Based Multiple Myeloma Cancer Modeling and the Related Study of the Balance between Osteoclasts and OsteoblastsTreatment of multiple myeloma bone disease: experimental and clinical data.Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays.Osteoblastogenesis and tumor growth in myeloma.Advances in the understanding of myeloma bone disease and tumour growth.Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myelomaBone disease in multiple myeloma: pathophysiology and management.Potential of resveratrol analogues as antagonists of osteoclasts and promoters of osteoblasts.Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKLLentivirus-mediated RNA interference of DC-STAMP expression inhibits the fusion and resorptive activity of human osteoclasts.Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myelomaConsequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone.In silico investigations of the anti-catabolic effects of pamidronate and denosumab on multiple myeloma-induced bone disease.Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells.Evidences of early senescence in multiple myeloma bone marrow mesenchymal stromal cells.Effect of zoledronate on oral wound healing in rats.The use of bisphosphonates in patients with breast cancer.Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse modelThe phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotypeMonoclonal gammopathies of undetermined significance: a review.Interpreting the molecular biology and clinical behavior of multiple myeloma in the context of global gene expression profiling.Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in boneAngiogenesis-related cytokines, RANKL, and osteoprotegerin in multiple myeloma patients in relation to clinical features and response to treatment.New insights into the pathophysiology and management of bone disease in multiple myeloma.Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivoThe Medical Research Council Myeloma IX trial: the impact on treatment paradigms.Myeloma cells inhibit osteogenic differentiation of mesenchymal stem cells and kill osteoblasts via TRAIL-induced apoptosis.Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myelomaMultiple myeloma/hypercalcemia.Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation.Myeloma as a model for the process of metastasis: implications for therapyTherapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growthBisphosphonates and bone metastases: current status and future directions.New therapeutic agents for the treatment of bone diseases.Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment.Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates.CD44 deficiency inhibits unloading-induced cortical bone loss through downregulation of osteoclast activity.
P2860
Q27011865-5C119EE0-A47D-45FE-B636-4A6E7D4EDF42Q28082335-CDD39FDD-8B58-45D2-924F-E68C3D08B04FQ28477867-CF38C5B2-C310-4BF7-83D1-C8E9DF8C3F15Q28551480-707D352C-A9F0-4500-B64C-F58FA9A973FCQ30868833-CB2F10BE-59B6-4791-AC55-805DCBE66F25Q33577408-A8B8E4F4-2EF2-4C77-B7C3-0AA28B0ABAFBQ33768466-4DF68DB4-63F5-4120-95E7-55AA31610C33Q33829022-5B7DC04E-D59E-46CC-8E9D-3B8970712B30Q33856318-0408E5B2-B3BB-47D4-B730-EAEDF00515D4Q34045789-C497F62A-83E9-4D60-9713-3E220DF18C19Q34242787-F95B5FAA-7CEE-4E7B-936B-66AFD05B3A38Q34267974-FB78F11C-287F-4919-811C-B49D0FA6B4A6Q34335082-A927E25E-4222-4738-AA60-B0ABDD3681E0Q34404651-4AC2D16E-876C-4057-A062-2A390E445D52Q34418934-AFA8C9A7-AA6A-438A-B6BE-BCD94774A293Q34427554-4108AAA8-14E4-4E9A-BE7F-19AE9EBBCA1FQ34448984-AD57FD4B-37BB-4646-86E7-2E026CCA1461Q34652128-6CABA5AC-A754-48BE-AEA1-66C9AA627586Q34694368-E74A7F9C-567E-4AFD-ABAD-B511550F7F4EQ35039488-A25F0306-E750-48EB-B0FA-F53E83BCA201Q35070415-6A3FA7E3-779E-468B-B37A-0710B40B95D6Q35070420-C58FA827-5FBF-4EF8-9F2F-5DA888F5ED50Q35170927-278A2F8A-8F4A-4E92-940D-9C9B70EEF9B7Q35170930-300BC603-5D1F-45C1-8C36-C5688B4411EBQ35219019-3F5E581F-5F86-402A-A8EF-B2419CD9BA35Q35220234-026FE57A-1E8A-4715-8D27-72ADD54FAE05Q35591086-315AF025-46B5-40CF-9DDD-4EF138DDDF2BQ35642745-385C469D-24E3-4CF8-AB6E-EED08CF2B120Q35700723-584FC129-5769-40AE-880A-DFC7FFC541EAQ35770718-73D0E8A7-9628-45A0-916B-67DF17FA448FQ35848298-800E7AF4-6484-4AEC-A8EE-0CC8F694BAEAQ35901084-D7CDA72A-3FD2-4413-A3AE-FDD94FEFCD55Q35955440-31D202AC-F85D-4B87-A0FC-BF52D2069F87Q36079800-662A214B-FC3B-42DC-BE95-517FDD9BEB8CQ36092153-63E1D397-1489-4B7C-B72D-46BD3FB9BEECQ36118409-6ABBCD9C-C418-42BD-B1A7-CDADC2531A05Q36161232-11C43D30-97AF-4BD9-BA52-FC6B267F1BBFQ36194583-3F365176-F1BB-4DCA-A314-CF5CA24BC949Q36217148-21897D3D-4511-4C45-AFE4-476D6A31AC38Q36245921-FAB80842-D0C6-4642-B98B-4201F4072DD8
P2860
Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Myeloma interacts with the bon ...... endent on osteoclast activity.
@en
Myeloma interacts with the bon ...... endent on osteoclast activity.
@nl
type
label
Myeloma interacts with the bon ...... endent on osteoclast activity.
@en
Myeloma interacts with the bon ...... endent on osteoclast activity.
@nl
prefLabel
Myeloma interacts with the bon ...... endent on osteoclast activity.
@en
Myeloma interacts with the bon ...... endent on osteoclast activity.
@nl
P2093
P2860
P1476
Myeloma interacts with the bon ...... endent on osteoclast activity.
@en
P2093
Cherie L Johnson
Joshua Epstein
Roger N Pearse
Yongwon Choi
P2860
P304
P356
10.1046/J.1365-2141.2002.03257.X
P407
P577
2002-02-01T00:00:00Z